Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T18:02:05.396Z.
Calculation as of: 2026-10-06T18:02:05.396Z.
Quote observation: 2026-10-06T17:58:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2d15fccd73dd71321fa30efb235d10704747171fee005d1a5dd6499fafc6c703
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Estrella Immunopharma, Inc.
Market Cap
$17.71M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$17.27M
EV/Sales Ratio
272.77x
TTM Avg
308.82x
3Y Avg
115.81x
5Y Avg
143.55x
Market Cap
$16.84M
EV/Sales Ratio
4.47x
TTM Avg
3.81x
3Y Avg
4.26x
5Y Avg
4.62x
Market Cap
$16.78M
EV/Sales Ratio
0.72x
TTM Avg
1.08x
3Y Avg
179.64x
5Y Avg
2065.58x
Market Cap
$16.64M
EV/Sales Ratio
0.65x
TTM Avg
0.67x
3Y Avg
1.03x
5Y Avg
10.93x
Market Cap
$18.81M
EV/Sales Ratio
N/A
TTM Avg
13.65x
3Y Avg
401.05x
5Y Avg
54100.66x
Market Cap
$16.55M
EV/Sales Ratio
1.02x
TTM Avg
10.15x
3Y Avg
24.96x
5Y Avg
21.29x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | $17.71M | N/A | N/A | N/A | N/A |
| Cosmos Health Inc. (COSM)vs › | $17.55M | 0.43x | 0.52x | 0.46x | 0.60x |
| PAVmed Inc. (PAVM)vs › | $17.27M | 272.77x | 308.82x | 115.81x | 143.55x |
| Lipocine Inc. (LPCN)vs › | $17.11M | 7.73x | 7.07x | 11.18x | 149.23x |
| Marker Therapeutics, Inc. (MRKR)vs › | $16.84M | 4.47x | 3.81x | 4.26x | 4.62x |
| Palatin Technologies, Inc. (PTN)vs › | $16.78M | 0.72x | 1.08x | 179.64x | 2065.58x |
| Bionano Genomics, Inc. (BNGO)vs › | $16.64M | 0.65x | 0.67x | 1.03x | 10.93x |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.81M | N/A | 13.65x | 401.05x | 54100.66x |
| TScan Therapeutics, Inc. (TCRX)vs › | $16.55M | 1.02x | 10.15x | 24.96x | 21.29x |
| Dyadic International, Inc. (DYAI)vs › | $16.44M | 5.78x | 10.55x | 12.56x | 17.17x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
